Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMS ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Facephi achieves outstanding results in RIVTD Track 3 Evaluation from Department of Homeland Security (DHS)1 in the USA This evaluation assessed the accuracy and robustness of biometric authentication ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related ...

Restructured convertible bond debt: Tailored approach to remove large debt overhang. New funding: Bondholders to provide CHF 150 million new money facility. US GAAP loss for global business of around ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Filing of daridorexant in Taiwan planned ...

The insomnia treatment Quviviq (daridorexant) is the company’s top-selling drug, bringing in revenue of $35.1m in 2023. Idorsia expects 2024 sales to reach $61.4m, with Muller saying the company ...

Idorsia’s Quviviq (daridorexant) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which means it is likely to be approved for use in around two months.